The peptide revolution in fat loss and metabolic optimization continues to accelerate, with pharmaceutical company Ascletis Pharma announcing the submission of two Investigational New Drug (IND) applications to the U.S. FDA for novel obesity treatments. These applications, reported by Yahoo Finance Singapore in early July 2026, represent a significant evolution in peptide-based weight management—targeting once-monthly injections that could reshape how the bodybuilding and biohacking communities approach body composition optimization.
For followers of Tony Huge and the TonyHuge.is platform, this development signals a potential shift in the peptide landscape beyond the familiar GLP-1 agonists like semaglutide and tirzepatide. The new candidates—ASC36, an amylin receptor agonist, and ASC36_35, a combination formulation—represent the pharmaceutical industry’s attempt to create more convenient, longer-lasting alternatives to current weight loss peptides that require weekly or even daily administration.
Understanding the New Peptide Candidates
Ascletis Pharma’s submission includes two distinct but related compounds designed for once-monthly administration—a dosing frequency that would represent a major convenience upgrade over existing peptide therapies in the fat loss space.
ASC36: The Amylin Receptor Agonist
The first candidate, ASC36, functions as an amylin receptor agonist. Amylin is a hormone naturally co-secreted with insulin by pancreatic beta cells, playing a crucial role in glucose homeostasis and appetite regulation. By activating amylin receptors, ASC36 aims to slow gastric emptying, suppress glucagon secretion, and reduce food intake—mechanisms familiar to those in the Tony Huge community who have experimented with various appetite-suppressing peptides.
What distinguishes this compound from research peptides currently discussed in biohacking circles is its pharmaceutical-grade development and once-monthly dosing protocol, achieved through advanced peptide engineering and formulation technology.
ASC36_35: The Triple-Agonist Combination
The second IND application covers ASC36_35 FDC (Fixed-Dose Combination), which co-formulates ASC36 with a GLP-1R/GIPR dual agonist peptide. This creates what is essentially a triple-agonist approach targeting three distinct pathways: amylin receptors, GLP-1 receptors, and GIP receptors.
This multi-targeted strategy mirrors trends Tony Huge has long discussed regarding peptide stacking and synergistic effects. The pharmaceutical industry appears to be validating the concept that targeting multiple metabolic pathways simultaneously may produce superior fat loss results compared to single-mechanism approaches.
Key Takeaways
- Extended Dosing Convenience: Once-monthly administration could eliminate the compliance issues associated with daily or weekly peptide injections
- Triple Mechanism Approach: The ASC36_35 combination targets amylin, GLP-1, and GIP receptors simultaneously for comprehensive metabolic effects
- Pharmaceutical Validation: Major pharma investment in peptide obesity treatments confirms the mechanisms biohackers have explored for years
- Future Availability: FDA approval process typically takes years, meaning underground research peptide markets will continue serving early adopters
- Potential Applications: Beyond obesity treatment, these mechanisms may benefit bodybuilders seeking enhanced nutrient partitioning and appetite control during cutting phases
Implications for the Bodybuilding and Biohacking Community
Tony Huge has extensively documented his experiences and research into various peptides for body composition optimization, including GLP-1 agonists and other metabolic modulators. The Ascletis IND submissions represent the pharmaceutical industry’s recognition of what the biohacking community has understood for years: peptides offer powerful tools for manipulating body composition and metabolic function.
The Move Toward Convenience
One persistent challenge with peptide protocols has been injection frequency and compliance. Weekly injections of semaglutide and tirzepatide already represented an improvement over daily protocols, but monthly administration would dramatically reduce the burden of peptide therapy. For bodybuilders managing multiple compounds during contest preparation or enhancement protocols, reducing injection frequency while maintaining efficacy would be highly valuable.
Synergistic Mechanisms
The decision to combine amylin agonism with GLP-1/GIP dual agonism in the ASC36_35 formulation demonstrates pharmaceutical acceptance of multi-pathway targeting—a strategy common in the experimental peptide community. Tony Huge’s work has frequently emphasized that combining compounds with complementary mechanisms often produces results exceeding what either compound achieves alone.
The amylin pathway specifically offers benefits beyond simple appetite suppression. By slowing gastric emptying and modulating glucagon, amylin agonists may improve nutrient partitioning—the preferential shuttling of nutrients toward muscle tissue rather than fat stores—a holy grail for bodybuilders seeking to maximize lean mass gains while minimizing fat accumulation.
Regulatory Timeline and Access Considerations
While the IND submission represents a significant milestone, the path from FDA application to market approval typically spans several years and multiple clinical trial phases. Phase 1 trials assess safety, Phase 2 evaluates efficacy and dosing, and Phase 3 involves large-scale confirmation studies. This timeline means that pharmaceutical-grade ASC36 and ASC36_35 won’t be widely available for several years at minimum.
This regulatory reality has historically created a divide between pharmaceutical development and the research peptide community that Tony Huge has documented extensively. Biohackers and bodybuilders seeking cutting-edge compounds often turn to research peptide suppliers rather than waiting years for FDA approval, accepting the risks associated with unregulated sources in exchange for early access to potentially beneficial compounds.
Quality and Safety Considerations
The pharmaceutical development process, while slow, does provide rigorous safety and quality data that research peptides lack. Ascletis will conduct extensive testing on dosing, side effects, drug interactions, and long-term outcomes—information that could prove valuable even to those using similar compounds from alternative sources.
As Tony Huge has consistently emphasized, self-experimentation with research compounds requires careful consideration of risks, quality verification through testing when possible, and close monitoring of biomarkers and physical responses.
The Broader Peptide Obesity Treatment Landscape
The Ascletis IND submissions occur within a rapidly evolving competitive landscape. Pharmaceutical giants have recognized that peptide-based obesity treatments represent a multi-billion dollar market, with compounds like Ozempic (semaglutide) and Mounjaro (tirzepatide) achieving blockbuster status.
The race to develop next-generation peptides with improved efficacy, reduced side effects, and enhanced convenience has intensified. Monthly dosing represents one differentiation strategy, while others are exploring oral formulations, transdermal delivery, and novel receptor targets.
For the bodybuilding and biohacking communities that Tony Huge serves, this pharmaceutical competition likely means continued innovation in peptide technology, with new mechanisms and formulations eventually trickling down to research peptide markets.
Practical Applications for Body Composition Goals
While ASC36 and ASC36_35 are being developed specifically for obesity treatment, the mechanisms they target have clear applications for physique optimization beyond simple weight loss. Competitive bodybuilders and fitness enthusiasts might find particular value in:
- Contest Preparation: Appetite suppression during aggressive caloric deficits helps maintain dietary adherence during cutting phases
- Nutrient Partitioning: Amylin’s effects on glucose metabolism may improve how the body allocates incoming nutrients
- Insulin Sensitivity: Multi-agonist approaches targeting incretin pathways can enhance insulin sensitivity, potentially benefiting both fat loss and muscle growth
- Post-Cycle Body Composition: Managing body composition during transition periods when hormonal profiles are fluctuating
Conclusion
Ascletis Pharma’s submission of IND applications for ASC36 and ASC36_35 represents another validation point for peptide-based approaches to metabolic optimization—approaches that Tony Huge and the biohacking community have explored and documented extensively. The pharmaceutical industry’s investment in once-monthly amylin and multi-agonist peptide formulations confirms the therapeutic potential of these mechanisms while highlighting the tension between regulatory caution and the desires of early adopters seeking immediate access to cutting-edge compounds.
As these compounds progress through clinical development, the bodybuilding and biohacking communities will be watching closely, not just for the eventual pharmaceutical products, but for the mechanistic insights and safety data that may inform ongoing self-experimentation with research peptides. The future of body composition optimization increasingly appears to be peptide-based, with new targets and improved formulations continually expanding the toolkit available to those pursuing peak physical performance and metabolic health.